Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) is now available.
Hangzhou Tigermed Consulting Co., Ltd. announced an update regarding its final cash dividend for the year ended December 31, 2024. The dividend, set at RMB 3 per 10 shares, will be paid on July 31, 2025, following shareholder approval on May 30, 2025. The announcement includes details on the withholding tax rates applicable to different categories of shareholders, with non-resident enterprises and individuals subject to a 10% tax and mainland individual investors facing a 20% tax. This update clarifies the default currency for dividend payment and emphasizes the company’s commitment to transparent financial practices, potentially impacting investor relations and market perception.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. operates in the consulting industry, providing clinical trial services and solutions primarily focused on the pharmaceutical and biotechnology sectors. The company is known for its comprehensive suite of services that support drug development and regulatory compliance, catering to a global market.
YTD Price Performance: -19.13%
Average Trading Volume: 121
Technical Sentiment Signal: Buy
Current Market Cap: €3.88B
For detailed information about 3347 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue